Recent Finacing
Recent Raise
Nuvation Bio develops and plans to commercialize oncology therapies, with lead asset taletrectinib and a clinical-stage pipeline of seven mechanistically distinct programs, operating from New York City.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Nuvation Bio.
